-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte Corporation Announces Promising 24-Week Phase 3 Results for Povorcitinib in Hidradenitis Suppurativa at EADV 2025 Congress

Reuters·09/17/2025 05:00:31

Please log in to view news